An observational study in Phenylketonurias, sponsored by University of Missouri-Columbia. Completed at 2 sites in United States. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-22.
Sponsored by University of Missouri-Columbia · Observational
PKU is a rare autosomal recessive condition associated with disruption in dopamine synthesis. Although early diagnosis and treatment prevent the severe impairments associated with untreated PKU, individuals with early-treated PKU (ETPKU) nonetheless experience significant sequelae, including impaired working memory and increased risk for anxiety problems. Past research with other clinical populations (e.g., generalized anxiety disorder) suggests that the two phenomena may be linked, with increased anxiety contributing to poorer WM performance. Currently we propose to initiate an exciting new line of research examining the potential relationship between anxiety and WM in ETPKU. The proposed study will also apply remote neuropsychological performance-based assessment to the study of ETPKU and thus overcoming the geographical limitations/challenges associated with recruitment of participants with this rare disease.
183 studies on the registry are indexed under Phenylketonurias; 38 are open to participants now.
This study's enrollment of 84 is above the median of 40 across 60 observational studies indexed under Phenylketonurias.
Browse Phenylketonurias studies →University of Missouri-Columbia is the lead sponsor of 357 studies on the registry; 70 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 28 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Individuals age 18-40 years old with and without PKU
Exclusion Criteria:
Adults with early-treated PKU
Other: nointervention
Adults without PKU who are otherwise healthy
Other: nointervention
Nointervention
Working Memory performance
Composite score based on multiple working memory-related CANTAB tests
Time frame: 2.5-3 hrs total over approx 1-3 weeks
Plan to share: Undecided — To be determined
No publications or documents are linked to this record.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Missouri-Columbia